PharmaSGP Releases Preliminary Half-Year Figures for 2025

PharmaSGP Holding SE, the German OTC pharmaceutical company, announced preliminary figures for the first half of 2025. The company recorded revenues of €66.0 million, marking a 13.0% increase from the previous year's €58.4 million. However, adjusted EBITDA saw a slight decline of 1.4%, dropping to €16.7 million from €16.9 million. This decrease is attributed to higher marketing and supply costs related to the expansion of the pureSGP brand.

Despite the dip in EBITDA, PharmaSGP projects revenues for the entire year to range between €132.0 million and €138.0 million, with an adjusted EBITDA between €37.0 million and €39.0 million. The company plans to further expand its pureSGP portfolio, anticipating changes in its margin structure over the coming years.